InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,346.99
(
-0.11%
)
US TECH 100
18,499.20
(
-0.19%
)
Dow Jones
38,798.99
(
-0.22%
)
Brent Oil
79.43
(
-0.57%
)
Bitcoin
69,236.38
(
-2.16%
)
Post# of 821321
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

budfoxfun

Send PM Follow Ignore
Followers 971
Posts 383037
Boards Moderated 6
Alias Born 06/24/2011

budfoxfun

Re: None

Tuesday, 01/09/2018 9:10:13 AM

Tuesday, January 09, 2018 9:10:13 AM

Post# of 821321
$ONCX HOUSTON, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Oncolix, Inc., (ONCX) announced today that the Company’s clinical site investigator has initiated patient recruitment for the second dosing group for the Prolanta™ Phase 1 clinical trial in patients with advanced ovarian cancer. Patient dosing is anticipated to begin during the first quarter of 2018. The drug supply for this dosing group is scheduled to be shipped to the clinic from the contract manufacturer during January.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up